TREK Therapeutics
Trek Therapeutics is a public benefit corporation dedicated to developing affordable medicines for infectious diseases worldwide. With deep expertise in virology and drug development, the company aims to create socially responsible and profitable treatments, starting with hepatitis C virus (HCV). Their strategy involves launching affordable HCV treatments in middle-income countries and leveraging tiered pricing to ensure accessibility across different economic settings.
Industries
Nr. of Employees
small (1-50)
TREK Therapeutics
125 CambridgePark Drive, Suite 301, Cambridge, MA 02140
Products
HCV protease inhibitor (acquired compound)
A small‑molecule HCV protease inhibitor acquired to be used in combination regimens for treatment of hepatitis C; developed for inclusion in short-duration combination therapy.
HCV NS5A inhibitor (acquired compound)
A non‑proprietary description of an NS5A inhibitor acquired for use in combination antiviral regimens targeting hepatitis C.
Non‑nucleoside HCV polymerase inhibitor (acquired compound)
A non‑nucleoside inhibitor of the HCV polymerase enzyme acquired for development in combination antiviral regimens.
IMPDH inhibitor with broad‑spectrum antiviral activity
An IMPDH inhibitor with demonstrated in vitro broad‑spectrum antiviral activity and filed use patent claims for activity against selected hemorrhagic fever viruses and other pathogens.
Preclinical nucleotide polymerase inhibitor (acquired compound)
A preclinical nucleotide inhibitor of viral polymerase acquired for development in hepatitis C and potentially other viral indications.
HCV protease inhibitor (acquired compound)
A small‑molecule HCV protease inhibitor acquired to be used in combination regimens for treatment of hepatitis C; developed for inclusion in short-duration combination therapy.
HCV NS5A inhibitor (acquired compound)
A non‑proprietary description of an NS5A inhibitor acquired for use in combination antiviral regimens targeting hepatitis C.
Non‑nucleoside HCV polymerase inhibitor (acquired compound)
A non‑nucleoside inhibitor of the HCV polymerase enzyme acquired for development in combination antiviral regimens.
IMPDH inhibitor with broad‑spectrum antiviral activity
An IMPDH inhibitor with demonstrated in vitro broad‑spectrum antiviral activity and filed use patent claims for activity against selected hemorrhagic fever viruses and other pathogens.
Preclinical nucleotide polymerase inhibitor (acquired compound)
A preclinical nucleotide inhibitor of viral polymerase acquired for development in hepatitis C and potentially other viral indications.
Services
Design and execution of mid-stage clinical trials including randomized, double-blind Phase 2a studies and planning for Phase 2b trials.
Formulation development, scale-up, continuous manufacturing implementation, reactor/mixing design, and process validation to support commercialization.
Identification and negotiation of licensing or collaboration opportunities for antiviral compounds and scientific platforms to accelerate development and access.
Development of market-entry strategies including regional launches, tiered pricing, and out-licensing to improve affordability and reach across different economic settings.
Exploration and implementation of blockchain-enabled protocols and other cold-chain solutions to secure and monitor pharmaceutical distribution.
Design and execution of mid-stage clinical trials including randomized, double-blind Phase 2a studies and planning for Phase 2b trials.
Formulation development, scale-up, continuous manufacturing implementation, reactor/mixing design, and process validation to support commercialization.
Identification and negotiation of licensing or collaboration opportunities for antiviral compounds and scientific platforms to accelerate development and access.
Development of market-entry strategies including regional launches, tiered pricing, and out-licensing to improve affordability and reach across different economic settings.
Exploration and implementation of blockchain-enabled protocols and other cold-chain solutions to secure and monitor pharmaceutical distribution.
Expertise Areas
- Clinical trial management
- Antiviral drug development
- CMC and pharmaceutical manufacturing
- Regulatory strategy and submissions
Key Technologies
- Small‑molecule antiviral therapeutics
- Antiviral combination therapy development
- In vitro antiviral and cell‑based assays
- Clinical trial methodologies (randomized, double‑blind Phase 2)
News & Updates
Trek Therapeutics in the News
Various articles and interviews highlighting Trek Therapeutics' activities and research.
Press Releases
Official announcements regarding clinical trials, licensing, and research progress.
Publications and Presentations
Research articles and conference presentations by Trek-affiliated members.
An article discussing Trek's approach to HCV treatment access.
Pharmafocus article from October 2017.
Milano Finanza article from August 2020.
Trek Therapeutics in the News
Various articles and interviews highlighting Trek Therapeutics' activities and research.
Press Releases
Official announcements regarding clinical trials, licensing, and research progress.
Publications and Presentations
Research articles and conference presentations by Trek-affiliated members.
An article discussing Trek's approach to HCV treatment access.
Pharmafocus article from October 2017.
Milano Finanza article from August 2020.